Development of cellular immune response after infant pneumococcal conjugate vaccinations - Pneumococcal cellular immune response

etherlands Vaccine Institute0 个研究点目标入组 100 人开始时间: 2008年7月23日最近更新: 2022年4月4日

适应症

试验速览

暂无简介。

•The children have to be of normal health (same health criteria apply as used in well-baby clinics when a child receives a vaccination, e.g. also children with small increases in temperature or cold are seen as children with normal health)
•They have to be willing and able to participate in the trial according to procedure
•Presence of a signed informed consent (the parents/legally representatives have
•given written informed consent after receiving oral and written information)
•The children have received or will receive the Prevenar® vaccinations according to the 3+1 schedule of the Dutch NIP
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Previous vaccinations with Prevenar® using a schedule that differs from the Dutch 3+1 schedule
•Previous vaccinations with other pneumoccocal vaccines
•Presence of a serious disease that requires medical care that can interfere with the results of the study
•Known or expected allergy/hypersensitivity against one of the vaccine ingredients
•(anamnestic, be alert if the child has had medical complaints after previous Prevenar® vaccinations)
•Known or suspected immunological disorder
•Previously administration of plasma products (including immunoglobulin), within three months of study enrolment
•Bleeding disorders

发起方

etherlands Vaccine Institute